The oral factor XIa inhibitor milvexian across a range of doses is associated with a lower risk of venous thromboembolism (VTE) after knee arthroplasty than subcutaneous enoxaparin (Lovenox) without ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback